Cellevolve is focused on developing and commercializing innovative cell therapies aimed at addressing neglected diseases. The company leverages technological advancements to enhance health outcomes through collaboration with global innovators. Their approach emphasizes the importance of bringing clinical-stage therapies through late-stage development and commercialization, utilizing a specialized platform known as Cellution. This platform integrates various technologies and partnerships, allowing for a tailored model of cell therapy that meets specific clinical needs.

In addition to their collaborative approach, Cellevolve has established a late-stage portfolio that includes two assets currently in clinical development, with their lead asset targeting Progressive Multifocal Leukoencephalopathy (PML) and positioned for Phase II/pivotal readiness. This strategic focus on advancing their pipeline underscores the company's commitment to harnessing cutting-edge cell therapy technologies to address critical health challenges effectively.

United States

Cellevolve - Cell therapies are revolutionizing the treatment of disease and are poised to transform health outcomes. Advances in biology and technology have enabled the development of innovation in a more distributed way than ever before: there is a wave of novel therapeutics in academic centers and biotechs around the world looking for partners to advance their inventions. That’s where we come in. Our approach is to bring clinical stage therapies through late stage development and commercialization by partnering with innovators at academic medical centers and small biotechs around the world.

Cellevolve

Company Details